Track topics on Twitter Track topics that are important to you
Germany’s Boehringer Ingelheim is partnering US company Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases. The research collaboration and license agreement will initially focus on the discovery and development of novel GalXC RNAi therapeutics for non-alcoholic steatohepatitis (NASH), a chronic liver disease for which there is currently no approved treatment.
Original Article: Boehringer Ingelheim and Dicerna in NASH PactNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...